Member Info for silverknight

looked at this 4 years ago and i t has gone nowhere. On the face of it this company is i ncredibly cheap but has failed miserably to deliver value to its shareholders

down to the value of Tern alone. Everything else in for nothing.

I have been in this for about 3 years and this is the lowest it's been. Economic uncertainties should underpin the gold price and if we achieve 100000 oz by 2020 this will be a substantial company. A lot of the costs should come from cashflow and £1 per share sp looks very achievable,

You wouldn't think so. I'm surprised the volume of the last couple of days hasn't pushed it higher. Those American figures give an equivalent sp of 35p and total value around £4-80 per share.

£100 (plus equipment)? Seriously-it's not going to happen. The clock s ticking. When's the next fundraising due?

At last we are seeing a bit of decent buying today (including you and me). The completion of the US sale will reduce losses and debt and provide additional working capital for the very promising pipeline. Better than issuing more shares at a knock down price!

You're well diversified then. Must be a full time job keeping tabs on them all. My favoured commodity is gold and this sector has some substantially undervalued members as well. This is my insurance policy should things turn really nasty. By the way, you probably know that IMM does have a couple of cancer drugs in the pipeline so not totally dependant on Lupuzor.

Yes you make valid points here. Big pharma has a great opportunity to acquire some great little companies at knockdown prices with potential blockbuster pipelines. Market sentiment is very poor just now but brave buyers might clean up. I sold out of IMM in December at 167p and they are down to around 12p. Tempting to buy back in (along with MTPH of course).

we're all dead. Last month people here were talking about an sp of 15p or 20p imminently. Didn't happen.

Very brave of you to risk so much on this tiddler. Hope you've got a decent spread of other shares. I think many investors(gamblers) fixate on one company and overcommit to it. I'm in this but also Angle and Evgen as I like pharma/bio companies. No doubt if we don't buy more of these now they will jump soon. That's the market for you.

I think Michu makes a fair point here. It's crazy that this company is worth less than a lot of London properties. Right now I don't feel great urgency to buy but will be watching it closely. The Brexit situation hangs like a dark cloud over us but as you know pharmas can turn in an instant and I'm quietly confident about the longer term.

Presumably you're adding vigorously to your holding at this knock down price? If it's only general market condtions that are causing the fall then it must be a bargain at this level

small potatoes to a company like Newmont. This could easily be backburnered for months or even years. Expect to see the get rich quick speculators (who weren't here before Newmont) fade away without early action. For longtermers hopefully the future is more secure.

because they have lost faith n this shambles of a company. Every current shareholder is losing money here.

I've pointed this out more than once but some people choose to live in fantasyland. Mankayan has been available for a long time now.

Yes there are positives. Well done for keeping a lid on overheads and not raising cash by a dilutive share issue. This is a high risk/high reward share particularly as the m/c is so small. We must trust their judgement on the US disposal. Always feels like a race against the clock.

has been a desperately disappointing long term investment. I bought Ten Alps 9 years ago at preconsolidation price of £4 per share. Guinness book of records for destruction of shareholder value? At least it's on a sounder footing now (hopefully).

a well thought out and constructively made comment!

If it's possible to produce these results under Mugabe then it can withstand anything. One of my biggest holdings - I think it will deliver in the end.

Whilst the sale will leave us cash rich pharma companies notoriously get through it pretty quickly. I can see this drifting further down in the short term but will be interested in buying more if it drops to c20p.